Results 31 to 40 of about 29,631 (205)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination [PDF]

Vaccines, 2021
Anaphylactic reactions were observed after Singapore’s national coronavirus disease 2019 (COVID-19) vaccination programme started in December 2020. We report the clinical and laboratory features of three patients in our institution who developed anaphylactic reactions after receiving the Pifzer BNT162b2 vaccine.
Xin Rong Lim, Bernard Pui Leung, Carol Yee Leng Ng, Justina Wei Lynn Tan, Grace Yin Lai Chan, Chien Mei Loh, Gwendolyn Li Xuan Tan, Valerie Hui Hian Goh, Lok To Wong, Chong Rui Chua, Sze Chin Tan, Samuel Shang Ming Lee, Hwee Siew Howe, Bernard Yu Hor Thong, Khai Pang Leong   +14 more
openaire   +3 more sources

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

The Journal of Infectious Diseases, 2021
Abstract A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Yaki, Saciuk, Jennifer, Kertes, Naama, Shamir Stein, Anat, Ekka Zohar   +3 more
openaire   +3 more sources

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART

Médecine et Maladies Infectieuses Formation, 2022
INTRODUCTION: Le risque de thrombocytopénies thrombotiques immunitaires induites par le vaccin ChAdOx1-nCoV19 a conduit la France à recommander une seconde dose par un vaccin ARNm chez les personnes
Lachâtre, M., Loubet, P., Ninove, L., Gilbert, C., Merrien, D., Carcowski, C., Verdon, R., Maakaroun-Vermesse, Z., Launay, O., Wittkop, L.   +9 more
openaire   +1 more source

Myocarditis after BNT162b2 vaccination in a healthy male

The American Journal of Emergency Medicine, 2021
Myocarditis following mRNA COVID-19 vaccination has recently been reported to health authorities in the United States and other countries. Cases predominately occur in young adult males within four days following the second dose of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines.
Watkins, Kevin, Griffin, Gregory, Septaric, Kristen, Simon, Erin L.   +3 more
openaire   +2 more sources

Adverse events upon BNT162b2 vaccination.

, 2022
Adverse events upon BNT162b2 vaccination.
Nicolas Escriou (17497), Georgia Giannopoulou (14149534), Eleni Ntoukaki (14149528), Abraham Pouliakis (3694663), Konstantinos Lazaridis (384402), Stavroula Labropoulou (10297409), Petros Eliadis (14149531), Eleni Gaitanarou (14149537), Gerasimina Tsinti (14149522), Peggy Lymberi (14149543), Alexios Dimitriadis (14149519), Andreas Mentis (183644), Evangelia Sotiropoulou (14149525), Marija Backovic (3087789), Avgi Mamalaki (325291), Ioannis Sarrigeorgiou (14149513), Dimitra Moschandreou (14149516), Elisavet Grouzi (14149540)   +17 more
core   +1 more source

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy [PDF]

Nature Medicine, 2021
Abstract Background: As mass vaccination campaigns against COVID-19 accelerate worldwide, there remains only limited evidence regarding vaccine effectiveness (VE) among pregnant women. Pregnant women have been shown to be at risk for severe COVID-19, resulting in adverse obstetrics outcomes, and their immune system is known to undergo ...
Noa Dagan, Noam Barda, Tal Biron-Shental, Maya Makov-Assif, Calanit Key, Isaac S. Kohane, Miguel A. Hernán, Marc Lipsitch, Sonia Hernandez-Diaz, Ben Y. Reis, Ran D. Balicer   +10 more
openaire   +5 more sources

Concomitant Peripheral and Pulmonary Arterial Thromboembolism 35 Days After SARS-CoV-2 mRNA Vaccine

Cam & Sakura Medical Journal, 2023
Although thromboembolism after ChAdOx1 vaccine has been extensively reported, this association was rarely reported after vaccination with BNT162b2. We present the case of an otherwise healthy patient who developed concomitant acute limb ischemia and ...
Ahmet Can Topçu, Abdurrahman Ekinci, Nihan Kayalar, Mehmed Yanartaş   +3 more
doaj   +1 more source

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era

Expert Review of Vaccines, 2023
Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein.
Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa   +3 more
doaj   +1 more source

Safety and efficacy of RNA vaccines: State of the art

Медицинская иммунология, 2021
This review describes principles of action and the method of delivery of mRNA molecules into cells, as well as some of developed RNA vaccines and the results obtained in their study, though they have not been authorized for use yet.
A. V. Blagov, A. A. Bukaeva, V. V. Makarov, Z. V. Bochkaeva   +3 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

Human Vaccines & Immunotherapeutics, 2023
This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women.
Chenchit Chayachinda, Kanokwaroon Watananirun, Chayawat Phatihattakorn, Sanitra Anuwutnavin, Suvimol Niyomnaitham, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Supattra Rungmaitree, Laddawan Jansarikit, Kobporn Boonnak, Patimaporn Wongprompitak, Sansnee Senawong, Avishek Upadhya, Zheng Quan Toh, Paul V. Licciardi, Kulkanya Chokephaibulkit   +16 more
doaj   +1 more source